Ashkan M. Abbey, MD
Areas of Focus | Vitreoretinal Surgery, Medical Retina, Director of Clinical Research – Texas Retina Associates, Dallas
Office Locations | Dallas Main, Rockwall
Certification | American Board of Ophthalmology
Languages Spoken | English, Farsi, Conversational Spanish
“Giving patients back their vision is one of the most rewarding things I can imagine. I love that I get to do interesting work that I’m passionate about and see it translate directly into vastly improved quality of life for the people I care for. I believe patients need to be heard and treated thoughtfully, and nothing is more important than fostering direct and open communication with my patients.”
Fellowship
Vitreoretinal Surgery
Associated Retinal
Consultants, P.C.
William Beaumont Hospital
Royal Oak, Michigan
Residency
Ophthalmology
Bascom Palmer Eye Institute
Miami, Florida
Internship
Scripps Mercy Hospital
San Diego, California
Medical School
Weill Cornell Medical College
New York, New York
- American Society of Retina Specialists
- American Academy of Ophthalmology
- Association for Research in Vision and Ophthalmology
- Alpha Omega Alpha Honor Society
- Principal Investigator, REGENXBIO – Ascent – Phase III – Subretinal RGX-314 for Neovascular Age-Related Macular Degeneration
- Principal Investigator, Valo Health, Inc. – SPECTRA – Phase II – OPL-0401 Oral Therapy for Non-Proliferative Diabetic Retinopathy with or without Diabetic Macular Edema
- Principal Investigator, EyePoint Pharmaceuticals, Inc. – DAVIO2 – Phase II – EYP- 1901, a Tyrosine Kinase Inhibitor, for Neovascular Age-Related Macular Degeneration
- Principal Investigator, F. Hoffman-La Roche Ltd. – GR43828 – Phase I – Open-Label of RO7446603 for Diabetic Macular Edema
- Principal Investigator, Apellis Pharmaceuticals, Inc. – APL2-GA-305-GALE – Phase III – Open-Label, Extension study to Evaluate the Long-Term safety and Efficacy of PEGCETACOPLAN in GA Secondary to ARMD
- Principal Investigator, F. Hoffman-La Roche Ltd.-GR40550-Pagoda-Phase III-Diabetic Macular Edema
- Co-Investigator, Neurotech Pharmaceuticals, Inc-NTMT-03-A-501-MacTel-Phase III- Macular Telangiectasia Type 2
- Co-Investigator, Aura Biosciences – AU-011-202 – Phase II – AU-011 via Suprachoroidal Administration with Primary Indeterminate Lesions and Small Choroidal Melanoma
- Principal Investigator, F. Hoffman-La Roche Ltd. – AVONELLE-X – Phase III – Open- Label Extension Study from Teneya – Faricimab for Neovascular Age-Related Macular Degeneration
- Principal Investigator, Alimera Sciences, Inc. – NEW DAY – Phase IV – Iluvien Implant as Baseline Therapy for Early Diabetic Macular Edema
-
Abbey AM, Patel K, Anand R, Chong D, Fish GE, Fuller DP, Fuller T, Wang R, Spencer WB, Coors LE. Toxic Posterior Segment Syndrome: Clinical Characteristics of 50 Eyes. Submitted to Ophthalmology in October 2023.
- Heier JS, et al., Abbey AM. Pegcetacoplan for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration (OAKS and DERBY): Two Multicentre, Randomised, Double-masked, Sham-Controlled, Phase 3 Trials. The Lancet. 2023 October; 402(10411), 1434-1448.
- Ali AA, Abbey AM. Macular Hole Closure with Intravitreal Dexamethasone Implant. OSLI Retina. 2023 August; 1, 1-2.
- Patel KG, Flores J, Abbey AM. Injectable Fluocinolone Implant for the Management of Chronic Postsurgical Cystoid Macular Edema in Vitrectomized Eyes. Retina. 2023 May.
- Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, Abbey AM, Almeida DRP, Avery RL, Banda HK, Barakat MR, Bhandari R, Chang EY, Haug SJ, London NJS, Mein L, Sheth VS, Wolfe JD, Singer MA, Danzig CJ. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study – 6 month results. Eye. 2023 May.
- Patel NA, et al., Abbey AM. Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity—A Multicenter Study. Ophthalmology. 2023 April; 130(4), 373-378.
- Abbey AM, Weng CY, Berrocal MH, Gupta OP. Tackle Secondary IOLs with Ease. Retina Today. January/February 2023; 26-29.
- Patel NA, et al., Abbey AM. Practice Patterns and Outcomes of Intravitreal Anti-VEGF Injection for Retinopathy of Prematurity: An International Multicenter Study. Ophthalmology. 2022 December; 129(12), 1380-1388.
- Patel KG, Abbey AM. A Toxic Side Effect of Dropless Surgery. Retina Today. 2022 November 1; 63-65.
- Patel KG, Hilton T, Choi RY, Abbey AM. Uveitis and Posterior Ophthalmic Manifestations Following the SARS-CoV-2 (COVID-19) Vaccine. Ocular Immunology and Inflammation. 2022 July; 30(5), 1142-1148.
- Abbey AM. “Subretinal Delivery of RGX-314: Gene Therapy for Neovascular Age-Related Macular Degeneration (nAMD).” Paper Presentation at the American Society of Retina Specialists Annual Meeting; July 30, 2023.
- Abbey AM. “The DAVIO Trial: A Phase I, Open-label, Dose-Escalation Study of a Single Injection of EYP-1901 (Vorolanib in Durasert® Platform) Demonstrating Reduced Treatment Burden in Wet Age-Related Macular Degeneration.” Paper Presentation at the Association for Research in Vision and Ophthalmology Annual Meeting – New Orleans, LA; April 23, 2023.
- Abbey AM. “Surprise Billing/Good Faith Estimates.” Faculty and Presenter at the 2023 American Society of Retina Specialists Business of Retina Meeting – Irving, TX; March 19, 2023.
- Abbey AM. “Sutureless Scleral-Fixated Intraocular Lens Techniques. Faculty and Presenter for Instructional Course: Secondary IOL Techniques for Retinal Specialists.” American Academy of Ophthalmology Annual Meeting – October 2, 2022.
- Abbey AM. “Injectable Fluocinolone Implant for the Management of Chronic Postsurgical Uveitis and Cystoid Macular Edema in Vitrectomized Eyes.” Paper (On Demand) Presentation at the American Society of Retina Specialists Annual Meeting; July 14, 2022.
- Abbey AM. “The Use of a Combination of Ozurdex (Dexamethasone Intravitreal Implant) and Eylea (Aflibercept) versus Eylea Monotherapy for Diabetic Macular Edema: Preliminary Data from a Prospective, Comparative Trial (COED Trial).” Paper Presentation at the Retina World Congress Annual Meeting – Fort Lauderdale, FL; April 14, 2022.
- Abbey AM. “Complications of Compounded Moxifloxacin-Triamcinolone.” Paper Presentation at the Vit-Buckle Society Annual Meeting – Las Vegas, NV; March 25, 2022.
- Abbey AM. “Sutureless Scleral-Fixated Intraocular Lens Techniques. Faculty and Presenter for Instructional Course: Secondary IOL Techniques for Retinal Specialists.” American Academy of Ophthalmology Annual Meeting – November 2021.
- Patel SN, Tang PH, Storey PP, Wolfe JD, Fein J, Shah SP, Chen E, Abbey AM, Ferrone PJ, Shah CP, Liang MC, Stem MS, Ali Khan M, Yonekawa Y, Garg SJ. “The Influence of Universal Face Mask Use on Endophthalmitis Risk after Intravitreal Anti-Vascular Endothelial Growth Factor Injections.” Paper Presentation at the American Academy of Ophthalmology Annual Meeting – New Orleans, LA; November 14, 2021.
- RK Maturi, Abraham P, Antoszyk AN, Patel SS, Bridges Jr. WZ, Holekamp NM, Abbey AM, Edwards AO, Bagheri N, Rashid A, Seddon JM, Khanani AM. “Phase IIa Open-Label Study of GEM103 in Genetically Selected GA Subjects: Study Outline, Baseline Characteristics and Update.” Poster Presentation at the American Academy of Ophthalmology Annual Meeting – New Orleans, LA; November 13, 2021.
- 2023 Top 10 Reviewer, Ophthalmic Surgery Lasers + Imaging (OSLI Retina)
- Journal of VitreoRetinal Diseases Distinguished Contributor Award, 2023
- American Society of Retina Specialists (ASRS) Senior Honor Award, 2021
- ASRS Top 10 Poster Award, 2021
- Fellow of the American Society of Retina Specialists, 2021
- ASRS Honor Award, 2019
- Allergan FIRST Program (Fostering Innovative Retina Stars of Tomorrow), 2016-2018
- Fellow, American Academy of Ophthalmology, 2016
- Editorial Board Member, Retina Specialist
- Editorial Board Member, ASRS Retina Atlas
- Reviewer, RETINA
- Clinical Assistant Professor, Ophthalmology, UT Southwestern Medical Center, Dallas, Texas, 2016 – present